BR0012865A - Uma forma amorfa aperfeiçoada da proxetil cefpodoxima - Google Patents

Uma forma amorfa aperfeiçoada da proxetil cefpodoxima

Info

Publication number
BR0012865A
BR0012865A BR0012865-1A BR0012865A BR0012865A BR 0012865 A BR0012865 A BR 0012865A BR 0012865 A BR0012865 A BR 0012865A BR 0012865 A BR0012865 A BR 0012865A
Authority
BR
Brazil
Prior art keywords
amorphous form
improved
cefpodoxime proxetil
improved amorphous
proxetyl
Prior art date
Application number
BR0012865-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Yatendra Kumar
Rakesh Kumar Arora
Kaptan Singh
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BR0012865A publication Critical patent/BR0012865A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0012865-1A 1999-07-30 2000-07-24 Uma forma amorfa aperfeiçoada da proxetil cefpodoxima BR0012865A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1036DE1999 IN191496B (ref) 1999-07-30 1999-07-30
PCT/IB2000/001024 WO2001009143A1 (en) 1999-07-30 2000-07-24 An improved amorphous form of cefpodoxime proxetil

Publications (1)

Publication Number Publication Date
BR0012865A true BR0012865A (pt) 2002-07-09

Family

ID=11092065

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012865-1A BR0012865A (pt) 1999-07-30 2000-07-24 Uma forma amorfa aperfeiçoada da proxetil cefpodoxima

Country Status (9)

Country Link
US (1) US6602999B1 (ref)
EP (1) EP1204667A4 (ref)
JP (1) JP2003506329A (ref)
CN (1) CN1371381A (ref)
AU (1) AU5839100A (ref)
BR (1) BR0012865A (ref)
IN (1) IN191496B (ref)
WO (1) WO2001009143A1 (ref)
ZA (1) ZA200200692B (ref)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT408226B (de) * 1999-05-05 2001-09-25 Biochemie Gmbh Kristalliner 7-(2-(2-formylaminothiazol-4-yl)-2
EP1373276A4 (en) 2001-02-27 2005-03-02 Ranbaxy Lab Ltd PROCESS FOR THE PRODUCTION OF CEFPODOXIM PROXETIL
KR20070054730A (ko) * 2004-10-18 2007-05-29 테바 파마슈티컬 인더스트리즈 리미티드 알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는방법
CN101287453A (zh) * 2005-05-16 2008-10-15 依兰药物国际有限公司 包含头孢菌素的毫微粒和控制释放组合物
KR100840132B1 (ko) * 2007-04-17 2008-06-23 재단법인서울대학교산학협력재단 포화 액체 이산화탄소를 사용한 세포독심 프록세틸의 건조
KR20150053963A (ko) * 2012-09-11 2015-05-19 닥터 레디스 레보러터리즈 리미티드 엔잘루타마이드 다형태 및 그의 제조
EP4324527A3 (en) 2012-09-11 2024-04-24 Medivation Prostate Therapeutics LLC Formulations of enzalutamide
ES3049645T3 (en) 2015-03-06 2025-12-17 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
WO2017046756A1 (en) * 2015-09-18 2017-03-23 Lupin Limited Proxetil and axetil esters of cefixime
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
EP3456722B1 (en) * 2016-05-09 2025-12-10 Anacor Pharmaceuticals, LLC Crystal forms of crisaborole in free form and preparation method and use thereof
JP2019518058A (ja) * 2016-06-16 2019-06-27 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. スピロ−オキシインドール化合物の固体状態形
JP2019526637A (ja) * 2016-09-06 2019-09-19 インデナ・ソチエタ・ペル・アチオニ 固体形態のインゲノール 3−(3,5−ジエチルイソオキサゾール−4−カルボキシラート)及びその調製方法
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
IL295609B2 (en) * 2017-02-01 2023-11-01 Atea Pharmaceuticals Inc Nucleotide hemisulfate salt for the treatment of hepatitis C virus
AU2018246257B2 (en) * 2017-03-30 2022-05-12 Merck Patent Gmbh Solid form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
SMT202300327T1 (it) * 2017-11-22 2023-11-13 Agios Pharmaceuticals Inc Forme cristalline di n-(4-(4-(ciclopropilmetil) piperazin-1-carbonil)fenil)chinolina-8-solfonammide
SG11202009443RA (en) * 2018-04-05 2020-10-29 Sumitomo Dainippon Pharma Oncology Inc Axl kinase inhibitors and use of the same
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
CN110251467A (zh) * 2019-06-26 2019-09-20 北京济美堂医药研究有限公司 一种无定形态头孢妥仑匹酯组合物的制备方法
CN110437259B (zh) * 2019-08-14 2021-12-07 中国药科大学 头孢泊肟酯柚皮素共无定形物及其制备方法
US20220380348A1 (en) * 2019-10-04 2022-12-01 Sumitomo Dainippon Pharma Oncology, Inc. Axl inhibitor formulations
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
EP4355319A4 (en) 2021-06-17 2025-01-22 ATEA Pharmaceuticals, Inc. BENEFICIAL ANTI-HCV COMBINATION THERAPY
CN119256126A (zh) 2022-05-23 2025-01-03 国立大学法人名古屋工业大学 用湿式纺丝法连续制造包含无机填料粒子的生物降解性纤维材料的方法、以及用该方法制造的棉絮状的骨再生材料

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223153A (en) 1979-02-09 1980-09-16 Eli Lilly And Company Crystalline forms of N-2-(6-methoxy)benzothiazolyl N'-phenyl urea
IT1165253B (it) 1979-07-12 1987-04-22 Blasinachim Spa Procedimento di fabbricazione di acido chenodesossicolico cristallino puro
US4486425A (en) 1980-09-30 1984-12-04 Sankyo Company Limited 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
ATE262533T1 (de) * 1991-09-07 2004-04-15 Aventis Pharma Gmbh Diastereomer des 3-cephem-4-carbonsäure-1-(- isopropoxycarbonyloxy)ethylesters und verfahren zu dessen herstellung
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
AT413383B (de) * 1998-01-09 2006-02-15 Sandoz Ag Verfahren zur isolierung eines diastereoisomerengemisches von cefpodoxim proxetil
KR100342943B1 (ko) 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물

Also Published As

Publication number Publication date
US6602999B1 (en) 2003-08-05
EP1204667A1 (en) 2002-05-15
AU5839100A (en) 2001-02-19
WO2001009143A1 (en) 2001-02-08
IN191496B (ref) 2003-12-06
ZA200200692B (en) 2003-05-28
EP1204667A4 (en) 2002-10-30
JP2003506329A (ja) 2003-02-18
CN1371381A (zh) 2002-09-25

Similar Documents

Publication Publication Date Title
BR0012865A (pt) Uma forma amorfa aperfeiçoada da proxetil cefpodoxima
CA1037949A (en) Cephalosporin derivatives
IE831527L (en) Preparation of azetidinooxazole derivatives
UY23757A1 (es) Procedimiento para la preparación de derivados de cefalosporina.-
AU2003301584A1 (en) Enzyme-catalyzed transesterifications of pendant carboxylic acid groups
BR0112598A (pt) Processo para a preparação de (r,s)-axetil cefuroxima cristalina de alta pureza
CA2103696A1 (en) A method for the acylation of the 7-amino group of the cephalosporanic ring
KR100667143B1 (ko) 가용성 측쇄 에스테르와 효소 아실라제를 사용하는 β-락탐 항균 물질의 합성법
CA2292618C (en) Improved precipitation process of 7-aminocephalosporanic acid (7-aca)
WO2003011871A3 (en) Intermediates in cephalosporin production
KR910018388A (ko) 세팔로스포린 제조방방방법
GB1497039A (en) Penicillins and cephalosporins
CN100368554C (zh) 酶催化“一锅法”制备β-内酰胺抗生素的方法
BR9301627A (pt) Processo para preparar cefalosporinas
ATE244248T1 (de) Herstellung von amino cephalosporansäurederivaten
AU8404701A (en) Butinol I esterase
DE60233307D1 (de) Verfahren zur herstellung optisch aktiver propoxyanilinderivate
DE60205635D1 (de) Einfaches enzymatisches Verfahren zur Herstellung von Cefazolin
FI58132B (fi) Foerfarande foer framstaellning av 3-metyl- 3-cefem-4-karboxylsyrafoereningar
EP0742219B1 (en) Preparation and use of 7-((2-carbo-alkoxy-1-methylethenyl) amino)-3-hydroxymethyl-3-cephem-4-carboxylic acids
WO2004081220A3 (en) A process for enzymatically resolving an enantiomeric mixture of alpha-hydroxy acids
AU4757000A (en) Method of producing methoxyimino acetic amide
GB1261780A (en) Orally active sulfur-containing cephalosporin antibiotics
KR890000497A (ko) 아실 유도체
DE60044276D1 (de) Esterase Gene und Verwendungen davon

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired